NCT05204160 2024-07-03
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Emory University
Phase 2 Withdrawn
Clinical Trials
6 trialsNCT04258683 2023-08-29
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Canadian Myeloma Research Group
Phase 2 Withdrawn
NCT05493618 2023-01-27
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Hackensack Meridian Health
Phase 1/2 Withdrawn
NCT04361851 2022-04-26
Study of Dara-Pembro for Multiple Myeloma Patients
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT03221634 2019-03-25
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT03191981 2017-08-24
MUKfourteen
University of Leeds
Phase 1/2 Withdrawn